Genentech, Inc.

Constellation Pharmaceuticals, Inc.

Sarah Bronner

Patrick Cyr

Fei Wang

Steven R Magnuson

F Anthony Romero

Vickie Hsiao-Wei Tsui

Kwong Wah Lai

John Wai

Monique Bodil Van Niel

Kevin X Chen

Christopher Hurley

James John Crawford

Richard Pastor

Benjamin Fauber

Andrew Peter Cridland

Emanuela Gancia

Stuart Ward

Jonathan Killen

Jeremy M Murray

Bing-Yan Zhu

Brian K Albrecht

Steven T Staben

Wendy Lee

Christopher McBride

Alexander M Taylor

Matthew Volgraf

Lynnie Lin Trzoss

Craig Stivala

Terry Crawford

Alexandre Cote

Jason R Zbieg

Alexandre Côté

Olivier Rene

Steven Elliot Kauder

Alberto Gobbi

Paul Winship

Jiangpeng Liao

Jackson G Egen

Marc Adler

Amogh Boloor

Nadezda V Sokolova

Jackson Egen

The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

Sulfonimidamide compounds as inhibitors of interleukin-1 activity

The present invention relates to a compound formula (I): and to salts thereof, wherein R, RX, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Therapeutic compounds and uses thereof

The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R-Rof formula (I) and R-Rof formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, p, q A, B, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Pyridazine derivatives as RORc modulators

Compounds of formula I: or pharmaceutical salts thereof,

The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R-Rof formula (I) and R-Rof formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Growing community of inventors

South San Francisco, CA, United States of America

Sarah Bronner